Emerging Drugs and Targets for Parkinson's Disease

Erscheinungsjahr 2013
ISBN: 978-1-84973-617-6
Verlag: Royal Society of Chemistry

Buch, Englisch, Band Volume 34, 402 Seiten, Format (B × H): 163 mm x 238 mm, Gewicht: 762 g

Reihe: Emerging Drugs and Targets for Parkinson's Disease

Affecting over 1.5 million people across the world, Parkinson's disease is a progressive neurological condition characterized, in part, by the loss of dopaminergic neurons in the substantia nigra pars compacta. It affects 1.5% of the global population over 65 years of age. As life expectancy is increasing, over the next few years the number of patients with Parkinson´s disease will grow exponentially. To date, there are no available treatments that are capable of curing Parkinson´s disease, and the current goal of therapy, dopamine replacement strategies, is to reduce symptoms. After several years of disease progression, treatment is complicated by the onset of motor fluctuations and dyskinesias. This information reveals the great importance and social need of finding an effective therapeutic intervention for Parkinson´s disease.

This exemplary new book reviews some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets currently undergoing the validation process to try to reach the Parkinson´s drug market in the next few years as potential disease modifying drugs. Providing up to date and comprehensive coverage, this book is essential reading for researchers working in academia and industry in any aspect of medicinal chemistry or drug discovery.

Autoren/Hrsg.

Martinez, Ana

Gil, Carmen

Fachgebiete

• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie

Inhaltsverzeichnis

Overview on Parkinson disease. Rational for pharmacological intervention;

Dopaminergic pathway and L-Dopa treatments. Future challenges;

COMT Inhibitors: present problems and relevance of the new ones;

MAO inhibitors for PD (Safinamide);

Dopamine agonist: present and future (Pardoprunox);

Therapies for dopaminergic-induced dyskinesias in Parkinson disease. (Fipamizole);

Beyond the dopamine receptor: regulation of protein phosphatases;

Molecular chaperones as rational drug targets for Parkinson's disease therapeutics;

Alpha-synuclein assembly as a therapeutic target of PD;

Alpha-synuclein (alpha-syn) phosphorylating polo-like kinase 2 (PLK2) as target for PD;

Hsp70 molecular chaperones and Parkinson's disease;

Glutamate receptors as therapeutic targets for Parkinson's disease;

Targeting adenosine A2A receptors in Parkinson's disease;

Leucine-rich repeat kinase-2 as target for Parkinson's disease;

Phosphodiesterase inhibitors for PD treatment;

P2X7 purinergic receptor: role in neurological disorders;

Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease;

D3 dopamine receptor agonists: neuroprotection in Parkinson's disease;

Antioxidants and PD;

Tryptophan metabolism in Parkinson's disease;

Grafted neural stem cell-derived dopaminergic neurons for PD Therapy;

Gene therapy for Parkinson's disease;

Carotid body autotransplantation in Parkinson disease;Neurotrophic factor therapy for Parkinson's disease

Über Autor(innen)

Gil, Carmen
Dr Carmen Gil is staff scientist at Center for Biological Research of Spanish National Council for Research (CSIC) with a background in Medicinal Chemistry and Pharmacy. She received her Ph.D. from Complutense University of Madrid in 2001. After a postdoctoral appointment at Bonn University (Germany) she joined the CSIC. Her research is oriented to the discovery and development of new small-molecules as innovative target-based drugs and her research areas have been focused on phosphodiesterase and kinase inhibitors as innovative drug candidates for neurodegenerative diseases. She is involved in different projects that apply her background and experience in the development of specific parasite phosphodiesterase and kinase inhibitors in the fight for neglected parasitic diseases. She is author of more than sixty scientific publications, has four active patents in the field and has contributed to several books.

Professor Martinez is a Research Professor at Instituto de Química Médica-CSIC. She has active research lines in the design and synthesis of new drugs for neurodegenerative diseases, searching for new targets to treat these devastating diseases. Currently, she ledas an interdisciplinary research group directed towards the discovery and development of new drugs for innovative targets in neurodegenerative disorders such as Alzheimer's Disease, Parkinson's Disease, Amyotrophic lateral sclerosis or Multiple Sclerosis.

Dr Gil obtained her PhD in Pharmaceutical Sciences from Universidad Complutense de Madrid before working with Prof. Dr. Stefan Bräse in the Kekulé Institute for Organic and Bioorganic Chemistry at the University of Bonn (Germany) where she was involved in the development of T1 triazene linker that has been successfully used as a linker for arenes. During this time she was a Marie Curie fellow of the European Union. She is currently working at the Instituto de Química Médica-CSIC, where she is responsible for the design and synthesis of biologically active organic molecules in the neurodegenerative field.